4-[(2,6-二甲基苯基)甲基]-3H-咪唑 | 78892-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[(2,6-二甲基苯基)甲基]-3H-咪唑
• 英文名称: MPV 207
• 英文别名: 4-(2,6-dimethyl-benzyl)-1H-imidazole；4-(2',6'-dimethylbenzyl)-imidazole；4(5)-(2,6-Dimethylbenzyl)imidazole；5-[(2,6-dimethylphenyl)methyl]-1H-imidazole
• CAS: 78892-44-1
• 化学式: C₁₂H₁₄N₂
• mdl: MFCD08668138
• 分子量: 186.257
• InChiKey: WWEDEECRSOOIGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二甲氨基甲酰氯 、 4-[(2,6-二甲基苯基)甲基]-3H-咪唑 生成 4-[(2,6-dimethylphenyl)methyl]-N,N-dimethylimidazole-1-carboxamide
  参考文献：
  名称：

  KIXARA, NORIAKI;TOMINO, KUNIO;TAN, XIROAKI

  摘要：

  DOI：

文献信息

• Hydrangea plant named ‘H218915’
  申请人：HYDRANGEA BREEDERS ASSOCIATION B.V.

  公开号：USPP032400P2

  公开（公告）日：2020-10-27

  A new and distinct cultivar of Hydrangea plant named ‘H218915’, characterized by its upright and uniformly mounded plant habit; vigorous growth habit and rapid growth rate; freely branching habit with strong, thick and sturdy stems; freely and uniformly flowering habit; lacecap-type inflorescences with numerous double sterile flowers that are white in color; and good postproduction longevity.

  一种新的独特的绣球植物品种，命名为“H218915”，其特征为：直立且均匀的丘陵状植株习性；生长势旺盛且生长速度快；自由分枝习性，具有强壮、粗壮的茎；自由且均匀开花习性；花序为蕾状花序，具有众多的白色双重不育花；并且具有良好的后期生产寿命。
• Substituted imidazole derivatives and their use as anti-thrombosis agents
  申请人：Farmos Yhtyma Oy

  公开号：US04514412A1

  公开（公告）日：1985-04-30

  Compounds of the formula: ##STR1## wherein each of R.sub.1, R.sub.2 and R.sub.3, which can be the same or different, is hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy, amino, hydroxy or nitro; R.sub.4 is hydrogen or alkyl of 1 to 7 carbon atoms; R.sub.5 is hydrogen or a straight or branched alkyl group of 1 to 5 carbon atoms or a phenyl group; and R.sub.6 is hydrogen or an alkyl group of 1 to 7 carbon atoms or a substituted or unsubstituted benzyl, X is --CH.sub.2 --, --CHOH-- or --CH.dbd.CH-- and n is 0-4; provided that R.sub.5 and R.sub.6 are simultaneously hydrogen only when n is 4 and X is --CH.dbd.CH--; and their non-toxic pharmaceutically acceptable acid addition salts and mixtures thereof exhibit valuable pharmacological activity and are useful in the treatment of mammals, especially as antithrombotic agents. Furthermore, some of the compounds have proved to possess antihypertensive or .beta.-blocking activity. Antimicrobial and antifungal properties have also been found. Processes for the preparation of these compounds are described, as are novel pharmaceutical compositions comprising at least one of the compounds or their salts.

  化合物的公式如下：##STR1## 其中R.sub.1，R.sub.2和R.sub.3可以相同也可以不同，取值为氢，氯，溴，氟，甲基，乙基，甲氧基，氨基，羟基或硝基；R.sub.4为氢或1至7个碳原子的烷基；R.sub.5为氢或1至5个碳原子的直链或支链烷基或苯基；R.sub.6为氢或1至7个碳原子的烷基或取代或未取代的苄基，X为--CH.sub.2--，--CHOH--或--CH.dbd.CH--，n为0-4；但当n为4且X为--CH.dbd.CH--时，R.sub.5和R.sub.6同时为氢。这些化合物的非毒性药物可接受酸盐和混合物表现出有价值的药理活性，并且在哺乳动物的治疗中非常有用，特别是作为抗血栓剂。此外，一些化合物已被证明具有抗高血压或β-阻滞活性。还发现具有抗微生物和抗真菌性质。描述了制备这些化合物的方法，以及至少包含其中一种化合物或其盐的新型制药组合物。
• Methods for treating CNS disorders with 4-imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197622A1

  公开（公告）日：2007-08-23

  The present invention relates to methods for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, Ar, R 1 , R 1′ , R 2 , and n are as defined in the specification and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神疾病，如精神分裂症、神经疾病，如帕金森病、神经退行性疾病，如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收的障碍、体温稳态的障碍和功能障碍、睡眠和昼夜节律的障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的R、Ar、R1、R1'、R2和n如规范中所定义，并且包括它们的药物活性盐、外消旋混合物、对映异构体和互变异构体。本发明还涉及化合物I的新型化合物、含有它们的组合物以及它们的制备方法。
• 4-Benzyl- and 4-benzoylimidazole derivatives, processes for their preparation and pharmaceutical compositions comprising the same
  申请人：Farmos-Yhtyma Oy

  公开号：EP0024829A1

  公开（公告）日：1981-03-11

  The invention provides compounds of the formula: wherein R1, R2 and R3, which can be the same or different, are each selected from hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy, amino, hydroxy and nitro; R4 is hydrogen or alkyl of 1 to 7 carbon atoms; -X- is wherein R5 is hydrogen, hydroxy or-OR6, and R6 is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atoms; and their non-toxic pharmaceutically acceptable acid addition salts and mixtures thereof. Processes for the preparation and use of the subject compounds are described, as are novel pharmaceutical compositions comprising at least one of the subject compounds or their salts. The compounds and their non-toxic salts exhibit valuable pharmacological activity and are useful in the treatment of mammals, particularly as anti-hypertensive or anti-ulcer agents. Furthermore, they are useful as diuretic, sedative, analgesic, anti-inflammatory and tranquilizing agents.

  本发明提供了如下式的化合物： 其中R1、R2和R3可以相同或不同，它们各自选自氢、氯、溴、氟、甲基、乙基、甲氧基、氨基、羟基和硝基；R4是氢或1至7个碳原子的烷基；-X-是 其中 R5 是氢、羟基或-OR6，R6 是 1 至 7 个碳原子的烷基或 6 至 10 个碳原子的芳基；以及它们的无毒药学上可接受的酸加成盐及其混合物。描述了制备和使用上述化合物的工艺，以及包含至少一种上述化合物或其盐的新型药物组合物。这些化合物及其无毒盐具有宝贵的药理活性，可用于治疗哺乳动物，特别是作为抗高血压或抗溃疡药物。此外，它们还可用作利尿剂、镇静剂、镇痛剂、消炎剂和镇定剂。
• Substituted imidazole derivatives and their preparation and use
  申请人：Farmos-Yhtyma Oy

  公开号：EP0058047A1

  公开（公告）日：1982-08-18

  Compounds of the formula: wherein each of R1, R2 and R3, wnich can be the same or different, is hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxy, amino, hydroxy or nitro; R4 is hydrogen or alkyl of 1 to 7 carbon atoms; R5 is hydrogen or a straight or branched alkyl group of 1 to 5 carbon atoms or a phenyl group; and R6 is hydrogen or an alkyl group of 1 to 7 carbon atoms or a substituted or unsubstituted benzyl, X is -CH2-, -CHOH-or -CH=CH- and n is 0-4; provided that R5 and R6 are simultaneously hydrogen only when n is 4 and X is -CH=CH-; and their non-toxic pharmaceutically acceptable acid addition salts and mixtures thereof exhibit valuable pharmacological activity and are useful in the treatment of mammals, especially as antithrombotic agents. Furthermore. some of the compounds have proved to possess anti- hypertensive or β-btocking activity. Antimicrobial and antifungal properties have also been found. Processes for the preparation of these compounds are described, as are novel pharmaceutical compositions comprising at least one of the compounds of their salts.

  式中的化合物： 其中R1、R2和R3可以相同或不同，各自为氢、氯、溴、氟、甲基、乙基、甲氧基、氨基、羟基或硝基；R4为氢或1至7个碳原子的烷基；R5 是氢或 1 至 5 个碳原子的直链或支链烷基或苯基；R6 是氢或 1 至 7 个碳原子的烷基或取代或未取代的苄基，X 是-CH2-、-CHOH-或-CH=CH-，n 是 0-4；但只有当 n 为 4 且 X 为-CH=CH-时，R5 和 R6 才同时为氢；它们的无毒药学上可接受的酸加成盐及其混合物具有宝贵的药理活性，可用于哺乳动物的治疗，特别是作为抗血栓药物。此外，其中一些化合物已被证明具有抗高血压或β-阻滞活性。此外，还发现了抗菌和抗真菌特性。本文介绍了这些化合物的制备过程，以及包含至少一种化合物及其盐类的新型药物组合物。